https://www.live-feeds.com/feed/f-d-a-approves-the-drug-daraxonrasib-that-s-poised-to-transform-pancreatic-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/f-d-a-approves-the-drug-daraxonrasib-that-s-poised-to-transform-pancreatic-cancerhttps://www.live-feeds.com/feed/f-d-a-approves-the-drug-daraxonrasib-that-s-poised-to-transform-pancreatic-cancer#u50956Fri, 28 Aug 2026 12:45:52 +0000The FDA approved daraxonrasib on August 26, 2026, as a once-daily oral pill for patients with previously treated metastatic pancreatic cancer. Manufactured by Revolution Medicines, the first-in-class RAS inhibitor doubled median survival compared to chemotherapy in clinical trials. Experts expect the drug to transform the treatment of a disease long considered difficult to treat due to an undruggable gene.Why it mattersMetastatic pancreatic cancer has historically offered physicians and patients very few treatment options. This approval introduces a targeted therapy designed to inhibit the RAS https://www.live-feeds.com/feed/f-d-a-approves-the-drug-daraxonrasib-that-s-poised-to-transform-pancreatic-cancerhttps://www.live-feeds.com/feed/f-d-a-approves-the-drug-daraxonrasib-that-s-poised-to-transform-pancreatic-cancer#u49819Thu, 27 Aug 2026 09:00:37 +0000The FDA has approved daraxonrasib, a drug manufactured by Revolution Medicines, for the treatment of previously treated metastatic pancreatic cancer. Clinical trial results showed the drug could nearly double life expectancy for pancreatic cancer patients. Daraxonrasib is a targeted therapy that has been hailed as a potential game-changer in the treatment of pancreatic cancer.Why it mattersPancreatic cancer is a deadly disease with limited treatment options. The approval of daraxonrasib offers new hope for patients with advanced pancreatic cancer. The drug's unique mechanism of action and